SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (487)9/16/1996 9:01:00 AM
From: WWS   of 4342
 
Richard, I'm not sure that what happens to a protease inhibitor has direct implications for PN355 or not. If the virus is already developing an immunity to protease inhibitors, then drugs with new modes of action such as PN355 may be highly desired. Frankly, I find it hard to believe that the present status between AIDS and the new standard treatment regime is the "end" of the story. But it may take awhile for new resistant strains of AIDS to emerge. Still, PRLN could still have a major part to play if they became a "low cost" provider of an effective AIDS treatment. This would be premised on their ability to get to market an effective "natural" treatment (not a drug per se) without incurring the tremendous cash outlay that would be necessary to develop a drug. I'm still not willing to classify PRLN as just another "me too"--at least not yet.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News